ライフサイエンスコーパス: somatostatin receptor

1 a category of NETs that does not express the somatostatin receptor.

2 could equally sequester G-proteins from the somatostatin receptor.

3 Galpha(oB) = Galpha(i2) > Galpha(oA) for the somatostatin receptor.

4 y of novel ligands for the G-protein-coupled somatostatin receptor.

5 tinguishable from response to the endogenous somatostatin receptor.

6 docrine tumors express different subtypes of somatostatin receptors.

7 ind and transduce human 293 cells expressing somatostatin receptors.

8 ence of ZnCl(2) and after blockade of type-2 somatostatin receptors.

9 , which express both bcl-2 messenger RNA and somatostatin receptors.

10 cells transfected with the five known human somatostatin receptors.

11 rent modulation by the alpha2-adrenergic and somatostatin receptors.

12 ailable to couple to alpha(2)-adrenergic and somatostatin receptors.

13 LC-1) that is sequentially homologous to the somatostatin receptors.

14 selectivity when evaluated against the other somatostatin receptors.

15 pioid, alpha2-adrenergic, M2 muscarinic, and somatostatin receptors.

16 GH12C1 and F4C1 cells, which lack endogenous somatostatin receptors.

17 All cells have inhibitory somatostatin receptors.

18 ronal protein gene product 9.5 [PGP9.5], and somatostatin receptor 1 [SSTR1]).

19 r (NOP), MCHR1, both orexin receptors (ORX), somatostatin receptors 1 and 2 (SSTR1, SSTR2), kisspepti

20 The binding affinity of somatostatin receptors 1 through 5 was evaluated in all

21 sodium iodide symporter (hNIS) and the human somatostatin receptor 2 (hSSR2) in the vaccinia-based OV

22 for quantitating 125I-SS14 binding to human somatostatin receptor 2 (hSST2) have been developed.

23 Somatostatin receptor 2 (SSTR2) is frequently overexpres

24 e gastrin-releasing peptide receptor (GRPR), somatostatin receptor 2 (SSTR2), and chemokine C-X-C mot

25 ntified between mu opioid receptor (MOR) and somatostatin receptor 2 (SSTR2).

26 Meningiomas are known to express somatostatin receptor 2 (SSTR2).

27 One may therefore generalize that somatostatin receptor 2 antagonists are sensitive to rad

28 ere the lowest-affinity radioligands, with a somatostatin receptor 2 binding affinity up to 60 times

29 bles detection of meningioma tissue based on somatostatin receptor 2 expression.

30 class A G protein-coupled receptors: SSTR2 (somatostatin receptor 2), CHRM2 (cholinergic receptor, m

31 for clinical assessment in the treatment of somatostatin receptor 2-expressing neuroendocrine tumors

32 led octreotate is an effective treatment for somatostatin receptor 2-expressing neuroendocrine tumors

33 important treatment option for patients with somatostatin receptor-2 (SSTR2)-expressing neuroendocrin

34 7)Lu-DOTATATE), where the latter targets the somatostatin receptor-2.

35 oval of ubiquitin acceptor residues from the somatostatin receptor 3 (SSTR3) and from the orphan GPCR

36 protein-coupled receptors (GPCRs), including somatostatin receptor 3 (Sstr3) and serotonin receptor 6

37 hese dynamics, we imaged single molecules of Somatostatin Receptor 3 (SSTR3, a GPCR) and Smoothened (

38 two G protein-coupled receptors (GPCRs)-the somatostatin receptor 3 and rhodopsin.

39 d P1s stretching 1.1 Mb from D15Mit30 to the somatostatin receptor 3 gene is reported, and the DNA in

40 Finally, the ciliary targeting signal of somatostatin receptor 3 needs to be directly recognized

41 , we demonstrate that, unlike the seven-span somatostatin receptor 3 or the leptin receptor that inte

42 e ciliary membrane protein and BBSome cargo, somatostatin receptor 3, and significantly reduces axone

43 ium enrichment of a chimera of rhodopsin and somatostatin receptor 3, where the dual Ax(S/A)xQ ciliar

44 A somatostatin receptor 5 antagonist, which blunts inhibit

45 rement of [35S]GTPgammaS binding mediated by somatostatin receptor activation in the presence of diff

46 th DAMGO did not affect the Kir3 response to somatostatin receptor activation.

47 adenoviral vector encoding the human type 2 somatostatin receptor (Ad5-CMVhSSTr2).

48 roof of principle studies with octreotide, a somatostatin receptor agonist, demonstrated it to be bet

49 a TGR5 antagonist alone or concurrently with somatostatin receptor agonists represents a potential th

50 eurons, alpha 2 adrenoceptors, mu-opioid and somatostatin receptors all activate the same potassium c

51 E is similar to that of other (68)Ga-labeled somatostatin receptor analogs.

52 a combination of SBI-115 and pasireotide, a somatostatin receptor analogue.

53 ptides which possess a high affinity for the somatostatin receptor and contain a chelator for the rad

54 med to characterize the interaction with the somatostatin receptor and the intracellular fate of 64Cu

55 g for 3 receptor systems--steroid receptors, somatostatin receptors, and growth factor receptors-are

56 Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already

57 backbone N-methylation approach to a potent somatostatin receptor antagonist series using the antago

58 ming developments in PRRT include the use of somatostatin receptor antagonists and alpha-emitting rad

59 Only Ad5-CMVhSSTr2-injected tumors expressed somatostatin receptors, as determined by immunohistochem

60 ing somatostatin and is suitable for imaging somatostatin receptor-bearing tumors.

61 (68)Ga-DOTATATE for high-quality imaging of somatostatin receptor-bearing tumors.

62 ecause these cells express all five types of somatostatin receptors before the initiation of their mi

63 tives led to structural perturbations of the somatostatin receptor-binding sequence relative to the R

64 de, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding

65 stimulation by paracrine inhibition, because somatostatin receptor blockade potently stimulated gluca

66 ch include binding to five recombinant human somatostatin receptors carried out in two independent la

67 At early developmental stages somatostatin receptors coupled predominantly to the curr

68 Thus, somatostatin receptor coupling to Ca2+ channels persiste

69 tatin analogues (e.g. sandostatin) acting at somatostatin receptors, CTAP which binds specifically to

70 varying glomerular filtration rates, kidney somatostatin receptor densities, tumor volumes, and rele

71 Hence, TBR reflects somatostatin receptor density more accurately than SUV a

72 Five different subtypes of somatostatin receptors, designated sst1-5, have been ide

73 Activation of somatostatin receptors endogenous to HEK293 cells or kap

74 To extend this concept, we have developed a somatostatin receptor-enhanced green fluorescent protein

75 l neuroendocrine tumors (NETs) overexpresses somatostatin receptors, especially the sst2 subtype.

76 maging in NOD-SCID mice bearing subcutaneous somatostatin receptor-expressing AR42J tumors.

77 In vitro uptake was studied in somatostatin receptor-expressing CA20948 and megalin or

78 matostatin analogs used for the diagnosis of somatostatin receptor-expressing neuroendocrine tumors (

79 cessfully applied for imaging and therapy of somatostatin receptor-expressing neuroendocrine tumors u

80 u-DOTATATE is a most effective treatment for somatostatin receptor-expressing neuroendocrine tumors.

81 abeled somatostatin analogs in patients with somatostatin receptor-expressing tumors is often perform

82 E and [(68)Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-expressing tumors, warranting tran

83 ons for diagnosis, staging, and restaging of somatostatin receptor-expressing tumors.

84 e for either tracer for PET/CT evaluation of somatostatin receptor-expressing tumors.

85 T/CT provides information on the location of somatostatin receptor-expressing tumors.

86 Imaging of somatostatin receptor expression is an established techn

87 hed changes in presynaptic dopamine, whereas somatostatin receptor expression remained constant.

88 Tumors were frozen and evaluated for somatostatin receptor expression using fluorescein-label

89 h metastatic neuroendocrine tumors with high somatostatin receptor expression were included.

90 Somatostatin receptor expression, which was not a previo

91 umors have been suggested to be a measure of somatostatin receptor expression.

92 UV) in tumors were suggested as a measure of somatostatin receptor expression.

93 s (27 men) with advanced tumors and enhanced somatostatin receptor expression.

94 flux rate (K(i)), as a representation of the somatostatin receptor expression.

95 ace levels of three different members of the somatostatin receptor family (SSTR) which have natural d

96 Meningiomas express members of the somatostatin receptor family.

97 Allelic variation in the five somatostatin receptor genes (Smstr) could contribute to

98 e of a cocktail of 3 radioligands binding to somatostatin receptors, GLP-1 receptors, and GIP recepto

99 Somatostatin receptors have been identified in a variety

100 mpetent adenovirus encoding the human type 2 somatostatin receptor (hSSTr2) and the herpes simplex vi

101 se of positron emitter-labeled compounds for somatostatin receptor imaging (SRI) has become attractiv

102 In this study, we selected the somatostatin receptor imaging agent DOTATOC as the found

103 Somatostatin receptor imaging has recently been introduc

104 intigraphy to evaluate the potential role of somatostatin receptor imaging in inflammatory bowel dise

105 Somatostatin receptor imaging is a valuable tool in the

106 been posed as a potential source of error in somatostatin receptor imaging through interference with

107 d theoretically lead to misinterpretation of somatostatin receptor imaging with (68)Ga-DOTATATE PET/C

108 Somatostatin receptor imaging with (68)Ga-DOTATATE PET/C

109 found on simultaneous CT or later MR, CT, or somatostatin receptor imaging.

110 95% confidence interval (CI) 1.52-4.77] and somatostatin-receptor imaging (OR 3.681, 95% CI 1.809-7.

111 cPanNENs is increased by the use of EUS and somatostatin-receptor imaging and is higher in specializ

112 ementary argument for replacing SPECT by PET somatostatin-receptor imaging.

113 r sensory cilia, inhibited enrichment of the somatostatin receptor in primary cilia.

114 e inhibitors to block desensitization of the somatostatin receptor in slices from morphine-treated an

115 Despite the lack of significant somatostatin receptors in the affected bowel, an unexpec

116 The expression of somatostatin receptors in the stimulated adrenals may be

117 octreotide scintigraphy, which binds to the somatostatin receptors in the tumor.

118 Activation of somatostatin receptors increases the rate of granule cel

119 adrenergic, prostaglandin E(2), M(1)Ach, and somatostatin receptors induced arrestin-2-GFP redistribu

120 A high density of somatostatin receptors is also present in most intestina

121 ns use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope wi

122 (68)Ga-labeled somatostatin receptor ligand PET imaging has recently be

123 A somatostatin receptor ligand that is easily radiolabeled

124 Octreotide, a somatostatin receptor ligand that targets somatotroph ad

125 ",N'''-tetraacetic acid (TETA)-octreotide, a somatostatin receptor ligand, inhibits the growth of CA2

126 Pharmacological treatments include somatostatin receptor ligands (such as octreotide, lanre

127 tial studies in the United States focused on somatostatin receptor ligands.

128 se delivered by (18)F-FDG- or (68)Ga-labeled somatostatin receptor ligands.

129 rodihydroxyphenylalanine (FDOPA), and (68)Ga somatostatin-receptor ligands in NETs has been expanding

130 er RNA was attached to Tyr(3)-octreotate for somatostatin receptor-mediated intracellular delivery.

131 gate 1 was taken up by Mec-1 cells through a somatostatin receptor-mediated mechanism.

132 ide sequence of the gene for the fifth mouse somatostatin receptor (msst5).

133 atostatin receptor-positive cells but not in somatostatin receptor-negative cells.

134 yed significantly higher binding affinity to somatostatin receptors on CA20948 rat pancreatic tumor m

135 Targeting dopamine and somatostatin receptors on corticotroph adenomas with cab

136 The high expression of somatostatin receptors on this neuroendocrine neoplasm o

137 Somatostatin receptor PET imaging has had a profound eff

138 Somatostatin receptor PET tracers such as [(68)Ga-DOTA,1

139 These studies incorporate the use of somatostatin receptor-positive AR42J rat pancreatic tumo

140 sing therapeutic candidate for patients with somatostatin receptor-positive cancer.

141 eotide binding to DNA increased over time in somatostatin receptor-positive cells but not in somatost

142 r moderately differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors of

143 111In-DTPA-octreotide after it localizes in somatostatin receptor-positive tissues and sought to det

144 is due to the selective uptake of AN-238 by somatostatin receptor-positive tissues.

145 (Y3-TATE) improved uptake of the peptide in somatostatin receptor-positive tissues.

146 They exhibited high binding affinities to somatostatin receptor-positive tumor cells (1.88-14.82 n

147 Mice bearing CA20948 somatostatin receptor-positive tumor xenografts were tre

148 ing results of (86)Y-CHX-A''-octreotide in a somatostatin receptor-positive tumor-bearing rat model a

149 introduced not only for the localization of somatostatin receptor-positive tumors but also for selec

150 predict that both are effective for imaging somatostatin receptor-positive tumors in vivo.

151 ty profile in children and young adults with somatostatin receptor-positive tumors.

152 lus 29% minor response rate in patients with somatostatin receptor-positive tumors.

153 a PET radiopharmaceutical for the imaging of somatostatin receptor-positive tumors.

154 opharmaceutical for targeted radiotherapy of somatostatin receptor-positive tumors.

155 eatment approach in inoperable or metastatic somatostatin receptor-positive tumors.

156 T patients from a group of 367 patients with somatostatin receptor-positive tumors.

157 tate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tum

158 raacetic acid) and PET can be used to detect somatostatin-receptor-positive tumors in humans.

159 e1-octreotide (OC) was developed for imaging somatostatin-receptor-positive tumors using conventional

160 , subtype-selective agonists for each of the somatostatin receptors provides a direct approach to def

161 ctable or metastatic; however, expression of somatostatin receptors qualifies it for peptide receptor

162 eptor-expressing neuroendocrine tumors using somatostatin receptor radioligands.

163 Agonists for serotonin, adenosine, and somatostatin receptors reliably activated a potassium-se

164 s within the third intracellular loop of the somatostatin receptor replaced the third intracellular l

165 were positive on [(111)In-DTPA(0)]octreotide somatostatin receptor scintigraphy (SRS) before treatmen

166 ents had negative imaging studies in the pre-somatostatin receptor scintigraphy (SRS) era, and 23 pat

167 Somatostatin receptor scintigraphy (SRS) has a high sens

168 Somatostatin receptor scintigraphy (SRS) is being increa

169 1In-DTPA-D-Phe1]-octreotide was approved for somatostatin receptor scintigraphy (SRS) of gastroentero

170 Only patients with negative conventional and somatostatin receptor scintigraphy (SRS) results were st

171 )I-metaiodobenzylguanidine ((123)I-MIBG) and somatostatin receptor scintigraphy (SRS) with (111)In-pe

172 brain, preferably with MR, together with the somatostatin receptor scintigraphy (SRS), in each clinic

173 Tc-hydrazinonicotinamide (HYNIC)-octreotide (somatostatin receptor scintigraphy [SSRS]) SPECT/CT, (68

174 elective angiography, and bone scanning) and somatostatin receptor scintigraphy done using [111In-DTP

175 s, by angiography in 40% of patients, and by somatostatin receptor scintigraphy in 70% of patients.

176 ocol with the commonly used 3-d protocol for somatostatin receptor scintigraphy in patients with gast

177 Somatostatin receptor scintigraphy is the single most se

178 neoplasm patients undergoing restaging with somatostatin receptor scintigraphy on a modern SPECT/CT

179 MRI, ultrasound; if unclear, angiography and somatostatin receptor scintigraphy since 1994 to determi

180 , or ultrasound; if unclear, angiography and somatostatin receptor scintigraphy since 1994.

181 Somatostatin receptor scintigraphy was as sensitive as a

182 Somatostatin receptor scintigraphy was performed on a pa

183 Somatostatin receptor scintigraphy was significantly bet

184 phy were positive in 28%, and the results of somatostatin receptor scintigraphy were positive in 58%.

185 For patients with negative results on somatostatin receptor scintigraphy, guidelines about the

186 modalities including endoscopic ultrasound, somatostatin receptor scintigraphy, long-acting octreoti

187 uted tomography, magnetic resonance imaging, somatostatin receptor scintigraphy, whole-body positron

188 1% for MRI, 62% for angiography, and 92% for somatostatin receptor scintigraphy.

189 In Zollinger-Ellison syndrome, somatostatin-receptor scintigraphy provides an excellent

190 Their infection was specific to target somatostatin receptors, since a synthetic somatostatin p

191 h (18)F-fluorodihydroxyphenyl-l-alanine PET, somatostatin receptor SPECT, CT, or MR imaging.

192 use enhances the efficiency of radiolabeled somatostatin receptor (sst) imaging.

193 cal and clinical studies have indicated that somatostatin receptor (sst)-expressing tumors demonstrat

194 ested for binding affinity at the five human somatostatin receptors (sst(1)(-)(5)).

195 for their binding affinity to the five human somatostatin receptors (sst(1-5)), as well as for their

196 feration of human aortic SMCs via binding to somatostatin receptors (sst2 and sst5) and ghrelin recep

197 The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cance

198 ptor radionuclide therapy using radiolabeled somatostatin receptor (SSTR) agonists are successfully u

199 dionuclide therapy (PRRT) using radiolabeled somatostatin receptor (SSTR) analogs is a common approac

200 have shown enhanced tumor targeting by novel somatostatin receptor (SSTR) antagonists compared with c

201 Radiolabeled somatostatin receptor (SSTR) antagonists have shown in v

202 ion of secreted somatostatin is prevented by somatostatin receptor (SSTR) antagonists.

203 avidity to somatostatin analogues suggested somatostatin receptor (SSTR) expression in VHL-HBs, offe

204 docrine neoplasms (NENs) have long relied on somatostatin receptor (SSTR) expression.

205 Somatostatin receptor (SSTR) imaging is widely used for

206 Somatostatin receptor (SSTR) ligands inhibit GH release,

207 Eligibility for somatostatin receptor (SSTR) radionuclide therapy uses t

208 Somatostatin receptor (sstr) scintigraphy for imaging an

209 Previously, we have shown somatostatin receptor (SSTR) subtype-specific regulation

210 te the signaling events mediated by specific somatostatin receptor (SSTR) subtypes, we expressed SSTR

211 fficacy, and safety of PRRT in patients with somatostatin receptor (SSTR)-expressing G3 NENs.

212 indium-111 complex, is already approved for somatostatin receptor (SSTR)-expressing tumor imaging in

213 r available imaging agents for patients with somatostatin receptor (SSTR)-positive neuroendocrine tum

214 Somatostatin receptor (SSTR)-targeted peptide receptor r

215 Somatostatin receptors (SSTR) are highly expressed in we

216 In vitro somatostatin receptors (SSTR)-binding affinities of P587

217 Interestingly, somatostatin receptor (sstr1) expression was increased b

218 ell as by their binding affinities to cloned somatostatin receptors (SSTR1-5).

219 n, Cebpd), as well as neuropeptide signaling somatostatin receptor (Sstr2).

220 The method's application to somatostatin receptor SSTR5 (no experimental structure a

221 pads for autocrine activation of a GPCR (the somatostatin receptor SSTR5) with its peptide agonist SR

222 These rare human tumors often express somatostatin receptors (SSTRs) and thus are clinically r

223 ely, for PRRT and PET examinations targeting somatostatin receptors (SSTRs) in patients affected by n

224 Overexpression of somatostatin receptors (SSTRs) in patients with neuroend

225 xamined the expression of mRNAs for the five somatostatin receptors (SSTRs) in the caudate putamen of

226 Expression of somatostatin receptors (SSTRs) was assessed by reverse-t

227 reduction of the elevated cAMP by targeting somatostatin receptors (SSTRs) with octreotide (OCT; a s

228 Because of the presence of cell membrane somatostatin receptors (SSTRs), many neuroendocrine tumo

229 orectal cancer, which is reported to express somatostatin receptors (SSTRs).

230 etermined to identify sterically constrained somatostatin receptor subtype 1 (sst(1)) selective scaff

231 has high affinity and selectivity for human somatostatin receptor subtype 1 (sst1).

232 The human somatostatin receptor subtype 2 (hSSTr2)-68Ga-DOTATOC re

233 of somatostatin receptor subtype 5 (SST5) to somatostatin receptor subtype 2 (SST2) action in these c

234 Somatostatin receptor subtype 2 (sst2) agonists inhibit

235 is recent in vitro and in vivo evidence that somatostatin receptor subtype 2 (sst2) antagonists are b

236 h bind selectively and with high affinity to somatostatin receptor subtype 2 (sst2) have been synthes

237 oendocrine tumors, target the high levels of somatostatin receptor subtype 2 (SSTR1; alias sst2) expr

238 Somatostatin receptor subtype 2 (SSTR2) has been used as

239 Human somatostatin receptor subtype 2 (SSTR2) has been used fo

240 E2A-Y3-TATE (64Cu-[2]) had high affinity for somatostatin receptor subtype 2 (SSTr2) in A427-7 cells.

241 Somatostatin receptor subtype 2 (sstr2) is a G-protein-c

242 Recently, the somatostatin receptor subtype 2 (SSTR2) selective antago

243 somatostatin with picomolar affinity for the somatostatin receptor subtype 2 (SSTR2) upregulated in s

244 his concept to a G protein-coupled receptor, somatostatin receptor subtype 2 (SSTR2), in pituitary ce

245 ormed a screen for drugs that upregulate the somatostatin receptor subtype 2 (sstr2).

246 rains engineered to functionally express the somatostatin receptor subtype 2 and exhibit agonist-depe

247 strategy, induction of high levels of human somatostatin receptor subtype 2 expression and selective

248 The somatostatin receptor subtype 2 is expressed on macropha

249 AMBF3-TATE bound the somatostatin receptor subtype 2 with high affinity (inhi

250 ibited unexpectedly high binding affinity to somatostatin receptor subtype 2, and showed excellent ph

251 Visualization of somatostatin receptor subtype 2, for oncologic purposes,

252 aging agent that binds with high affinity to somatostatin receptor subtype 2, found on many human can

253 ed with Cu and (64)Cu and tested in vitro in somatostatin receptor subtype 2-overexpressing HEK-293 c

254 n to have the highest affinity yet found for somatostatin receptor subtype 2.

255 ncreased for cells expressing high levels of somatostatin receptor subtype 2.

256 Somatostatin receptor subtype 2A (sst2A) mediates many o

257 The somatostatin receptor subtype 3 (Sstr3) is selectively t

258 To assess the contribution of somatostatin receptor subtype 5 (SST5) to somatostatin r

259 r neuronal compartments, one of which is the somatostatin receptor subtype SST(3).

260 (HSVtk) for molecular chemotherapy and human somatostatin receptor subtype-2 (hSSTR2) for indirect im

261 Resected carotid plaques were retrieved for somatostatin receptor subtype-2 (sst2) immunohistochemic

262 ium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-binding PET trace

263 Somatostatin receptor subtype-4 (SSTR4) agonists have be

264 We have isolated and sequenced the mouse somatostatin receptor subtype-4-encoding gene (mSSTR4).

265 ding profile, with high binding affinity for somatostatin-receptor subtype 5.

266 structure of octreotide that binds to three somatostatin receptor subtypes (sst 2/3/5) with signific

267 The study of the five somatostatin receptor subtypes (SSTx, where x is the sub

268 (68)Ga-DOTANOC has high affinity for somatostatin receptor subtypes 2, 3, and 5 (sst2,3,5).

269 All somatostatin receptor subtypes are coupled to inhibition

270 Thus, by expressing individual somatostatin receptor subtypes in pituitary cells, we ha

271 hin intracellular domain 3 are shared by the somatostatin receptor subtypes SSTR1, -3, and -4, which

272 axis, we showed that rat hepatocytes express somatostatin receptor subtypes-2 and -3 and that IGF-I m

273 (68)Ga-DOTATOC, a somatostatin receptor-targeted ligand, has been used cli

274 ly, offers the possibility of using a single somatostatin receptor-targeted peptide conjugate as a th

275 We evaluated whether somatostatin receptor-targeted radionuclide therapy with

276 s when designing metal-peptide complexes for somatostatin receptor targeting.

277 tly higher affinity (IC50 = 0.15 nM) for the somatostatin receptor than the anti diastereomer (IC50 =

278 Carcinoid tumors have high numbers of somatostatin receptors that allow scintigraphic imaging

279 cate that there are multiple elements in the somatostatin receptors that can determine the binding af

280 alt-labeled octreotide analogs targeting the somatostatin receptor to identify promising candidates f

281 lity of peptide MIII-4 as well as endogenous somatostatin receptors to activate endogenous G(i) and t

282 2) (SRIF numbering), at the five known human somatostatin receptors transfected into and stably expre

283 Somatostatin receptor type 2 (SSTR2) expression and (68)

284 Selective antagonism of somatostatin receptor type 2 (SSTR2) normalizes glucagon

285 ECTIVE This study evaluated the influence of somatostatin receptor type 2 (SSTR2) polymorphisms on me

286 ly to locate tumors overexpressing primarily somatostatin receptor type 2 (SSTR2).

287 Thus, a selective somatostatin receptor type 2 antagonist (SSTR2a) should

288 orally with an adenovirus containing a human somatostatin receptor type 2 gene chimera (Ad-HA-SSTR2)

289 emonstrate a lack of ciliary localization of somatostatin receptor type 3 (Sstr3) and melanin-concent

290 The sulfonylurea receptor (Sur) and somatostatin receptor type 5 (SSTR5) play an integral ro

291 Little information is available about the somatostatin receptor types which may be involved in med

292 stern blotting revealed the presence of five somatostatin receptor types, sst1, sst2, sst3, sst4 and

293 of the potassium conductance induced by the somatostatin receptor was also blocked by compound 101 i

294 nity of nonradioactive (185/187)Re-P2045 for somatostatin receptors was compared in human NCI-H69 and

295 -specific desensitization of the M(1)Ach and somatostatin receptors was significantly attenuated in a

296 Nonpeptide agonists of each of the five somatostatin receptors were identified in combinatorial

297 metal cyclization, as well as binding to the somatostatin receptor, were investigated.

298 e physiological roles played by type 3 and 5 somatostatin receptors which are still far from being fu

299 The somatostatin receptor, which is overexpressed by many ne

300 of [111In-DTPA-DPhe1]octreotide scanning for somatostatin receptors, which these tumors characteristi